Asia Pacific Interventional Cardiology Device Market Will Continue to Grow Strongly Through 2022, Especially in China and India

July 9, 2014

Efforts to Reduce Overstenting and Price Competition Will Somewhat Restrict Market Expansion, According to Findings from Decision Resources Group

BURLINGTON, Mass., July 9, 2014 /PRNewswire/ — Decision Resources Group finds that the market for interventional cardiology (IC) devices still holds considerable potential for growth in the Asia Pacific, despite stagnating in recent years in the United States and Europe. This is particularly true in China and India, where expanding economies are allowing the governments to direct more money to improving health care infrastructure and physician training.


Other key findings from Decision Resources Group’s coverage of the Asia Pacific market for IC devices:

    --  Procedure volumes: Percutaneous coronary intervention (PCI) volume
        growth will decelerate through 2022; China's PCI growth rates in
        particular will come down from historic highs, with only single-digit
        procedure growth from 2018 onward. However, total PCI volumes will still
        more than double in the Asia Pacific region by 2022.
    --  Reducing overstenting: Intravascular imaging catheters and pressure
        guidewires are gaining attention in the Asia Pacific because these
        devices can help reduce cases of overstenting, which has become a
        greater concern globally. There has been a particular push to reduce
        overstenting in Australia and China, resulting in especially strong
        adoption of these technologies in these countries.
    --  Declining prices: Prices will decline in each of the Asia Pacific
        countries through 2022. In China, the tendering process for device
        purchasing is driving prices down, while in South Korea, strict
        reimbursement policies restrict device pricing. China and India also
        have strong presences of low-cost domestic manufacturers. Even in
        Australia, where domestic competition is less of a factor, there is
        significant pressure from the government to reduce health care costs and
        therefore device pricing.

Comments from Decision Resources Group Analyst Darren Lin:

    --  "Currently, bioresorbable vascular scaffolds (BVS) are only available in
        India of the Asia Pacific countries. However, Abbott, the first-mover in
        this space, is anticipated to receive approval for its ABSORB stent in
        Australia in late 2014, South Korea in 2015 and China in 2016. Although
        this technology has gained significant interest, more clinical evidence
        is needed before the use of BVS becomes widespread."
    --  "MicroPort Medical, a Chinese manufacturer, has managed to lead the
        large Chinese drug-eluting stent (DES) market despite strong competition
        from well-recognized major international manufacturers. The company is
        also currently promoting its next-generation Firehawk DES; however,
        similar to BVS, more clinical evidence is required to prove the validity
        of this technology, which features a dissolving polymer coating."

Additional Resources:

    --  Darren Lin has written a Medtech 360 report on this subject entitled
        Asia Pacific Markets for Interventional Cardiology Devices 2014.
    --  Decision Resources Group's Marketrack, which provides market share data
        by brand for the IC device market, can be found here.

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group

Christopher Comfort



Logo – http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Source: PR Newswire

comments powered by Disqus